Conference Correspondent

High Levels of Interferon Type I in Plasma of Patients with Lupus Predict Future Renal Disease

Conference Correspondent - Conference Correspondent

Elevation of interferon type I (IFN-I) is associated with more severe disease in patients with systemic lupus erythematosus (SLE), although the relationship between elevated levels of IFN-I and SLE disease activity over time has not been defined. In particular, lupus nephritis is the most common severe manifestation of SLE and confers an increased risk for end-stage renal disease and death in patients with SLE. In a new retrospective study, Kirou and colleagues (ACR 2013; Abstract 1572) analyzed plasma samples from 57 patients with SLE for IFN-I levels, as well as clinical and other laboratory data, longitudinally over an average of 9 visits per patient. The IFN-I levels were analyzed based on the response of the WISH cell line to SLE patient plasma, which is sensitive to IFN-I stimulation and has a minimum detection level of 6 IU/mL when assayed using quantitative PCR. Normal plasma and a recombinant IFN-I standard were used as negative and positive controls, respectively.  The patients were divided into 2 groups based on high or low IFN-I levels at baseline (study initiation).

Patients with SLE and high IFN-I plasma activity at baseline showed a 3.2-fold increased IFN-I plasma activity during follow-up visits compared with patients with low IFN-I plasma activity at baseline (P <.01). Compared with patients with low IFN-I plasma activity at baseline, the patients with high IFN-I plasma activity had significant decreases in peripheral blood C3 levels (P <.03), white blood cell counts (P <.04), absolute lymphocyte counts (P <.01), and a higher erythrocyte sedimentation rate (P <.02) and anti–ds-DNA titers (P <.02). Patients with high plasma IFN-I activity at the first study visit exhibited 1.4-fold greater disease activity during the study as measured by the SLE Disease Activity Index (SLEDAI; P <.02) or the British Isles Lupus Assessment Group (BILAG; P <.05).

Strikingly, patients with SLE and high IFN-I activity at study initiation demonstrated a 2.5-fold increase in renal BILAG activity (which can translate to a greater likelihood of developing lupus nephritis and end-stage renal disease), a 1.8-fold increase in neurologic BILAG activity, and worsened hematologic BILAG scores.

The authors concluded that measurement of IFN-I activity in plasma of patients with SLE may help identify patients at high risk for lupus nephritis and thus serve as an important disease monitoring biomarker. Furthermore, IFN-I appears to predict increased disease activity in neurologic and hematologic systems as detected by BILAG scores. However, for these conclusions to be useful, the measurement of plasma IFN-I must be made readily available and affordable for routine clinical practice.

Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: February 14, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME